2025 highlights in kidney cancer: TiNivo-2 and PDIGREE

Описание: Wenxin Xu, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of recent and upcoming influential kidney cancer trials, including the Phase III TiNivo-2 trial (NCT04987203), which demonstrated the inferiority of tivozanib plus nivolumab over tivozanib alone, as well as the Phase III PDIGREE trial (NCT03793166) of nivolumab and ipilimumab with cabozantinib. Dr Xu additionally highlights updates in adjuvant pembrolizumab and triplet therapies incorporating lenvatinib or belzutifan. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.